Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  2. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  3. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  4. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  5. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  6. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  7. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  8. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  9. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  10. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  11. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  12. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  13. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  14. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  15. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  16. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  17. He R, et al. 2021. J Immunol. 206:2353. PubMed
  18. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  19. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  20. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  21. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  22. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  23. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  24. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  25. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  26. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  27. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  28. Toomer G, et al. 2022. Viruses. 14:. PubMed
  29. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  30. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  31. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  32. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  33. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  34. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  35. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  36. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  37. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  38. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  39. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  40. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  41. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  42. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  43. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  44. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  45. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  46. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  47. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  48. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  49. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  50. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  51. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  52. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  53. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  54. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  55. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  56. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  57. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  58. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  59. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  60. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  61. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  62. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  63. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  64. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  65. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  66. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  67. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  68. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  69. White C, et al. 2014. J Immunol. 193:5933. PubMed
  70. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  71. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  72. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  73. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  74. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  75. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  76. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  77. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  78. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  79. He X, et al. 2021. Small. 17:e2007165. PubMed
  80. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  81. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  82. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  83. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  84. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  85. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  86. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  87. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  88. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  89. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  90. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  91. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  92. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  93. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  94. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  95. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  96. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  97. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  98. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  99. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  100. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  101. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  102. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  103. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  104. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  105. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  106. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  107. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  108. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  109. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  110. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  111. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  112. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  113. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  114. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  115. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  116. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  117. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  118. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  119. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  120. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  121. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  122. Lang V, et al. 2021. Elife. 10:. PubMed
  123. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  124. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  125. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  126. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  127. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  128. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  129. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  130. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  131. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  132. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  133. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  134. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  135. Ma K, et al. 2022. iScience. 25:104347. PubMed
  136. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  137. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  138. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  139. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  140. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  141. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  142. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  143. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  144. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  145. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  146. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  147. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  148. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  149. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  150. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  151. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  152. Li J, et al. 2020. Development. :. PubMed
  153. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  154. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  155. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  156. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  157. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  158. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  159. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  160. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  161. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  162. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  163. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  164. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  165. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  166. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  167. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  168. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  169. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  170. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  171. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  172. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  173. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  174. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  175. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  176. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  177. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  178. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  179. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  180. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  181. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  182. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  183. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  184. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  185. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  186. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  187. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  188. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  189. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  190. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  191. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  192. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  193. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  194. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  195. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  196. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  197. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  198. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  199. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  200. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  201. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  202. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  203. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  204. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  205. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  206. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  207. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  208. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  209. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  210. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  211. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  212. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  213. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  214. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  215. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  216. Gawish R, et al. 2022. Elife. 11:. PubMed
  217. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  218. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  219. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  220. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  221. Zeng A, et al. 2020. Oncol Rep. . PubMed
  222. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  223. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  224. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  225. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  226. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  227. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  228. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  229. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  230. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312691 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV™ 395 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account